Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NVRO 
Nevro Corp (NVRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NVRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -42.16% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 224.48M USD | Price to earnings Ratio - | 1Y Target Price 6.53 |
Price to earnings Ratio - | 1Y Target Price 6.53 | ||
Volume (30-day avg) 1313432 | Beta 0.94 | 52 Weeks Range 3.17 - 14.43 | Updated Date 03/27/2025 |
52 Weeks Range 3.17 - 14.43 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When After Market | Estimate -0.67 | Actual -0.6459 |
Profitability
Profit Margin -27.77% | Operating Margin (TTM) -21.79% |
Management Effectiveness
Return on Assets (TTM) -9.95% | Return on Equity (TTM) -43.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 183105352 | Price to Sales(TTM) 0.55 |
Enterprise Value 183105352 | Price to Sales(TTM) 0.55 | ||
Enterprise Value to Revenue 0.45 | Enterprise Value to EBITDA -4.79 | Shares Outstanding 38372000 | Shares Floating 34225556 |
Shares Outstanding 38372000 | Shares Floating 34225556 | ||
Percent Insiders 2.84 | Percent Institutions 104.91 |
Analyst Ratings
Rating 2.56 | Target Price 5.6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 11 | Sell 3 | Strong Sell 2 | |
Strong Sell 2 |
Upturn AI SWOT
Nevro Corp
Company Overview
History and Background
Nevro Corp, founded in 2006, focuses on developing and commercializing innovative neuromodulation solutions for patients suffering from chronic pain. It has grown to become a leader in spinal cord stimulation (SCS) technology.
Core Business Areas
- Spinal Cord Stimulation (SCS) Systems: Development, manufacturing, and commercialization of SCS systems, primarily the Senza system, for chronic pain management.
Leadership and Structure
The company is led by CEO Kevin Thornal. The organizational structure consists of departments for R&D, manufacturing, sales, marketing, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Senza Spinal Cord Stimulation System: The Senza system is Nevro's flagship product. It delivers HF10 therapy for chronic pain management. Market share data is dynamic but estimations place it around 25%. Competitors include Medtronic (MDT), Boston Scientific (BSX), and Abbott (ABT).
Market Dynamics
Industry Overview
The neuromodulation industry is experiencing growth driven by an aging population, increasing prevalence of chronic pain, and technological advancements in pain management solutions.
Positioning
Nevro Corp is a key player in the SCS market, distinguished by its HF10 therapy. Its competitive advantage lies in its differentiated technology and clinical evidence.
Total Addressable Market (TAM)
The TAM for SCS is estimated to be several billions of dollars annually. Nevro is positioned to capture a significant share of this market, particularly through continuous innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Innovative HF10 therapy
- Strong clinical evidence
- Growing market share
- Dedicated focus on chronic pain
Weaknesses
- Reliance on a single product (Senza)
- Relatively smaller size compared to larger competitors
- High R&D and marketing expenses
- Dependence on reimbursement approvals
Opportunities
- Expanding into new geographic markets
- Developing new applications for HF10 therapy
- Acquiring complementary technologies or products
- Increasing awareness and adoption of SCS
Threats
- Competition from larger, well-established players
- Pricing pressures from healthcare providers
- Technological advancements by competitors
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Boston Scientific (BSX)
- Abbott (ABT)
Competitive Landscape
Nevro's advantage is HF10 therapy, but it faces stiff competition from larger, more diversified companies like Medtronic, Boston Scientific, and Abbott, which have greater resources for R&D, marketing, and distribution.
Major Acquisitions
Viperide
- Year: 2021
- Acquisition Price (USD millions): 3
- Strategic Rationale: To expand the technology of its core business area.
Growth Trajectory and Initiatives
Historical Growth: Nevro has experienced periods of rapid revenue growth, particularly in the early years of Senza's commercialization. Growth has moderated more recently.
Future Projections: Analyst projections suggest continued revenue growth, but profitability remains a key challenge. Successful expansion into new markets and applications is critical.
Recent Initiatives: Recent initiatives include expanding sales efforts, investing in R&D for next-generation products, and pursuing strategic partnerships.
Summary
Nevro is a promising player in the neuromodulation space with its innovative HF10 therapy. While showing revenue growth, profitability remains a challenge. The company needs to expand its product line and geographic reach to compete effectively against larger competitors. Successfully navigating reimbursement hurdles is also crucial for long-term success.
Similar Companies
- MDT
- BSX
- ABT
- SNY
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nevro Corp
Exchange NYSE | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-06 | President, CEO & Director Mr. Kevin R. Thornal | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1099 | Website https://nevro.com |
Full time employees 1099 | Website https://nevro.com | ||
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.